Oxy17Fusion™

A Nano Emulsion Oxygen Therapeutics for Ischemic Tissue Diagnosis and Rescue, in Cardiology, Neurology and Oncology; by increasing Oxygen Transport during the reversible injury and recovery phases. It is a ready to use, stable IV injectable, available at the point of use without any blood group matching.

RTL has the world’s largest production source of Oxy-17® Gas, an enriched form of naturally available oxygen, in compliance with the cGMP requirement for medical gases, and commercially available in the United States and European Union for more than 30 years.

Technology: Introducing Oxy17Fusion™

Oxy17Fusion™ is the new cost-effective Theranostics medium innovation that could expand the reach of hospitals and clinics using the installed MRI equipment to perform metabolic imaging. It is works with current MRI equipment eliminating need for new Capex (Radioisotope based imaging), setup of new hot labs including training of specialized personnel required with currently.

Current metabolic imaging is restricted to hospitals with hot labs facilities using radioactive agents that are hazardous, inefficient and restrictive in their ability to be re-applied in short intervals. There is a critical and un met clinical need for timely real-time HD imaging of cellular metabolic function to detect stroke, heart attack and in neoplasm’s management for providing timely and optimal treatment.

Oxy17Fusion™ is the new cost-effective Theranostics medium innovation that could expand the reach of hospitals and clinics using the installed MRI unique carrier is an FDA approved PFD, stabilized emulsion oxygenated with our proprietary patented Oxy-17®. This enables revival of dying cells and accurate real-time monitoring. Oxy17Fusion™ is the new cost-effective Theranostics medium innovation that could expand the reach of hospitals and clinics using the installed MRI can provide an in vivo Enhanced Oxygen delivery once the diagnostic MRI imaging is completed. The lungs work to deliver enriched Oxygen to hypoxic or ischemic tissue. Studies have shown a 50% reduction in infarcts size when perfused with the emulsion compared to saline and hyperoxemia. OxyFusion’s small molecular size penetrates to oxygenate, and revive dying cells in areas affected by flow occlusion such as blood clots. Why settle for the old way of doing things? At Rockland Technimed, that’s the question we asked ourselves – and the answer was " Oxy17Fusion™ is the new cost-effective Theranostics medium innovation that could expand the reach of hospitals and clinics using the installed MRI ".

Technology

Upon obtaining regulatory approval, Oxy17Fusion™ is the new cost-effective Theranostics medium innovation that could expand the reach of hospitals and clinics using the installed MRI will be the only non-radioactive MRI metabolic imaging agent available on the market today. It could replace current imaging methods that employ the use of potentially dangerous radioactive agents, which also eliminates the need for expensive cyclotron and hot laboratory setup. It effectively provides critical metabolic information timely using conventional, readily available MRI equipment – which greatly increases access, lowers costs and the need for specially-trained personnel.

Additionally, Oxy17Fusion™ is the new cost-effective Theranostics medium innovation that could expand the reach of hospitals and clinics using the installed MRI is the only product that solves this problem and provides the impressive additional benefit of delivering oxygen to oxygen-starved tissue. This fact places us squarely within the growing field of theranostics, or personalized, therapy-based diagnostics. With the built-in ability to use OxyFusion with any existing MRI equipment, markets are opened up both domestically and globally – giving us the potential to act as a true market leader.

Technology
Technology

Theranostics

The process we use is natural cellular respiration. The Oxy17Fusion™ is the new cost-effective Theranostics medium innovation that could expand the reach of hospitals and clinics using the installed MRI emulsion, which is pre-dissolved Oxy-17Gas, is IV injected into the target area. Instead of radioactive elements, it utilizes oxygen – one of the most readily available elements on our planet – to impact the targeted tissue and make it detectable to an MRI

Technology

This is where the dual-pronged diagnostic/therapeutic benefits come into play. Oxy-17® then bypasses blockage and gets delivered directly to the oxygen-starved tissue, providing much-needed relief to cells suffering from hypoxia. By observing this process, physicians can then calculate the rate at which the oxygen is being consumed (OEF) and eventually deliver a successful diagnosis and treatment.

The Oxy17Fusion™ Uses

With this process, not only is the targeted tissue getting a valuable infusion of oxygen, but the diagnostic process also gets underway. The oxygen helps to display the cells’ metabolic processes, which can then be viewed using standard MRI equipment. Some of OxyFusion’s more common uses include :

  • Stroke: tPA= Bleeding risk *”Time is brain”
  • Heart Attack: Thrombolytics, anti platelet agents thinners increase bleeding risk
  • Carotid Stenosis: Ultrasound struggles to differentiate between total and pre-occlusive disease imprecise location(s) identified with duplex ultrasound.
  • Cancer Treatment: Radiation is imprecise, indiscriminant Trauma Blood loss):Blood supply-chain known issues (refrigeration, quantity, pathogens, type) Field application limitations
  • Trauma:Bleeding risk, needs fluid replacement that oxygenates to gain time to treatment
Patient Benefit
  • Timely assessment and intervention during reversible injury phase possible due to precise metabolic status of tissue at risk to guide intervention
  • Enables triaging of care as per the risk of tissue function
  • Optimal use of resources at medical facilities
  • Reduced downstream disabilities